Free Trial

Akero Therapeutics (AKRO) Competitors

Akero Therapeutics logo
$53.80 -0.11 (-0.20%)
Closing price 04:00 PM Eastern
Extended Trading
$53.72 -0.08 (-0.16%)
As of 07:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

AKRO vs. SMMT, ASND, RDY, VTRS, ROIV, BBIO, MRNA, QGEN, ELAN, and VRNA

Should you be buying Akero Therapeutics stock or one of its competitors? The main competitors of Akero Therapeutics include Summit Therapeutics (SMMT), Ascendis Pharma A/S (ASND), Dr. Reddy's Laboratories (RDY), Viatris (VTRS), Roivant Sciences (ROIV), BridgeBio Pharma (BBIO), Moderna (MRNA), QIAGEN (QGEN), Elanco Animal Health (ELAN), and Verona Pharma PLC American Depositary Share (VRNA). These companies are all part of the "pharmaceutical products" industry.

Akero Therapeutics vs. Its Competitors

Akero Therapeutics (NASDAQ:AKRO) and Summit Therapeutics (NASDAQ:SMMT) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, profitability, institutional ownership, media sentiment, risk and dividends.

In the previous week, Summit Therapeutics had 19 more articles in the media than Akero Therapeutics. MarketBeat recorded 24 mentions for Summit Therapeutics and 5 mentions for Akero Therapeutics. Akero Therapeutics' average media sentiment score of 1.01 beat Summit Therapeutics' score of 0.48 indicating that Akero Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Akero Therapeutics
4 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Summit Therapeutics
8 Very Positive mention(s)
2 Positive mention(s)
9 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Akero Therapeutics presently has a consensus target price of $73.38, indicating a potential upside of 36.38%. Summit Therapeutics has a consensus target price of $31.14, indicating a potential upside of 66.18%. Given Summit Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Summit Therapeutics is more favorable than Akero Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Akero Therapeutics
1 Sell rating(s)
7 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.31
Summit Therapeutics
4 Sell rating(s)
2 Hold rating(s)
11 Buy rating(s)
1 Strong Buy rating(s)
2.50

Akero Therapeutics' return on equity of -15.84% beat Summit Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Akero TherapeuticsN/A -15.84% -14.59%
Summit Therapeutics N/A -278.57%-241.80%

4.6% of Summit Therapeutics shares are owned by institutional investors. 7.1% of Akero Therapeutics shares are owned by company insiders. Comparatively, 84.9% of Summit Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summit Therapeutics has higher revenue and earnings than Akero Therapeutics. Akero Therapeutics is trading at a lower price-to-earnings ratio than Summit Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Akero TherapeuticsN/AN/A-$252.06M-$2.00-26.90
Summit Therapeutics$700K19,887.16-$221.32M-$1.01-18.55

Akero Therapeutics has a beta of -0.29, indicating that its stock price is 129% less volatile than the S&P 500. Comparatively, Summit Therapeutics has a beta of -1.13, indicating that its stock price is 213% less volatile than the S&P 500.

Summary

Summit Therapeutics beats Akero Therapeutics on 11 of the 15 factors compared between the two stocks.

Get Akero Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for AKRO and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AKRO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AKRO vs. The Competition

MetricAkero TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$4.31B$3.48B$6.22B$10.69B
Dividend YieldN/A2.27%5.72%4.87%
P/E Ratio-26.9023.0629.1427.22
Price / SalesN/A476.60577.13128.70
Price / CashN/A47.5937.5161.65
Price / Book5.0010.6612.476.59
Net Income-$252.06M-$52.56M$3.32B$276.14M
7 Day Performance-0.02%4.97%1.87%0.02%
1 Month Performance18.97%16.48%8.40%3.60%
1 Year Performance74.11%14.95%63.49%32.76%

Akero Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AKRO
Akero Therapeutics
3.7605 of 5 stars
$53.80
-0.2%
$73.38
+36.4%
+72.6%$4.31BN/A-26.9030
SMMT
Summit Therapeutics
3.0335 of 5 stars
$22.93
+7.4%
$31.29
+36.4%
-5.6%$15.86B$700K-22.70110Trending News
Earnings Report
Analyst Forecast
Options Volume
ASND
Ascendis Pharma A/S
3.0334 of 5 stars
$208.43
-0.5%
$248.29
+19.1%
+58.0%$12.93B$393.54M-40.391,017News Coverage
Analyst Upgrade
Gap Up
RDY
Dr. Reddy's Laboratories
2.4528 of 5 stars
$14.36
+0.1%
$16.95
+18.1%
-7.5%$11.97B$3.81B21.7527,811Positive News
VTRS
Viatris
3.5019 of 5 stars
$9.86
+1.2%
$10.40
+5.5%
-12.3%$11.36B$14.74B-3.4032,000
ROIV
Roivant Sciences
2.7102 of 5 stars
$16.21
+1.1%
$19.94
+23.0%
+48.8%$10.95B$29.05M-23.16860
BBIO
BridgeBio Pharma
4.6007 of 5 stars
$55.96
+0.8%
$63.94
+14.3%
+116.2%$10.61B$221.90M-13.68400Analyst Forecast
MRNA
Moderna
4.2962 of 5 stars
$26.74
-0.3%
$41.81
+56.4%
-49.6%$10.48B$3.24B-3.555,800Trending News
Analyst Forecast
QGEN
QIAGEN
4.1848 of 5 stars
$47.30
+1.0%
$49.40
+4.4%
+16.5%$10.41B$1.98B27.955,765Positive News
ELAN
Elanco Animal Health
2.7355 of 5 stars
$20.04
+1.4%
$19.14
-4.5%
+67.7%$9.82B$4.44B23.309,000Analyst Forecast
VRNA
Verona Pharma PLC American Depositary Share
1.568 of 5 stars
$106.91
flat
$109.00
+2.0%
N/A$9.21B$42.28M-107.9930Positive News

Related Companies and Tools


This page (NASDAQ:AKRO) was last updated on 10/21/2025 by MarketBeat.com Staff
From Our Partners